Sefaxersen not checked

Roche

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified in the protocol.”In the company’s words, NCT05797610 on ClinicalTrials.gov
Tested for
Primary IgA Nephropathy
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.”In the company’s words, NCT05797610 on ClinicalTrials.gov

Other drugs for Primary IgA Nephropathy

All 39 drugs for Primary IgA Nephropathy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 25 May 2028 A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Sefaxersen

Following is part of Solo: you see every change to Sefaxersen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in